{"id":"W3009494891","doi":"10.1056/nejmoa1904398","title":"Long-Acting Cabotegravir and Rilpivirine for Maintenance of HIV-1 Suppression","year":2020,"lang":"en","type":"article","venue":"New England Journal of Medicine","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":565,"is_retracted":false,"has_abstract":true,"ca_institutions":"GlaxoSmithKline (Canada)","funders":"Janssen Pharmaceuticals; ViiV Healthcare","keywords":"Rilpivirine; Medicine; Confidence interval; Liter; Clinical endpoint; Internal medicine; Reverse-transcriptase inhibitor; Human immunodeficiency virus (HIV); Integrase inhibitor; Pharmacotherapy; Viral load; Randomized controlled trial; Antiretroviral therapy; Virology","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001797132,0.0003779736,0.0007946501,0.0001989322,0.0001820327,0.0003553698,0.0005225876,0.0005096047,0.005049617],"category_scores_gemma":[0.001602471,0.0001567957,0.0005370984,0.0001846414,0.0004373059,0.0003775138,0.0002427635,0.00114172,0.0002515964],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0003571594,"about_ca_system_score_gemma":0.000638935,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.000415613,"about_ca_topic_score_gemma":0.001332208,"domain_scores_codex":[0.9993442,0.0003855525,0.00005176594,0.00007458419,0.00008820391,0.0000557135],"domain_scores_gemma":[0.9989154,0.000377728,0.0003517178,0.00006059998,0.00004041675,0.0002541762],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.7054235,0.01516087,0.01008062,0.002225096,0.001284314,0.0001101922,0.0001816158,0.001783588,0.0153316,0.0005069781,0.001375167,0.2465364],"study_design_scores_gemma":[0.6789767,0.274025,0.03568933,0.0002926262,0.0007944542,0.0004104382,0.00006703947,0.002594298,0.003419469,0.0005793027,0.003122384,0.0000289431],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9921721,0.00483615,0.0004600997,0.0002829847,0.00005770599,0.0007866197,0.0002288729,0.000022401,0.001153106],"genre_scores_gemma":[0.995915,0.001087595,0.001404111,0.0001968058,0.00007979165,0.0006712255,0.0001894709,0.000002951789,0.00045302],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.005049617,"threshold_uncertainty_score":0.01689267,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.02603651210254818,"score_gpt":0.2850169726029176,"score_spread":0.2589804605003694,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}